209 related articles for article (PubMed ID: 30726846)
1. Second Trimester Biochemical Markers as Possible Predictors of Pathological Placentation: A Retrospective Case-Control Study.
Berezowsky A; Pardo J; Ben-Zion M; Wiznitzer A; Aviram A
Fetal Diagn Ther; 2019; 46(3):187-192. PubMed ID: 30726846
[TBL] [Abstract][Full Text] [Related]
2. Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete.
Zhou J; Li J; Yan P; Ye YH; Peng W; Wang S; Wang XT
Placenta; 2014 Sep; 35(9):691-5. PubMed ID: 25063251
[TBL] [Abstract][Full Text] [Related]
3. First trimester maternal serum biochemical markers of aneuploidy in pregnancies with abnormally invasive placentation.
Thompson O; Otigbah C; Nnochiri A; Sumithran E; Spencer K
BJOG; 2015 Sep; 122(10):1370-6. PubMed ID: 25639820
[TBL] [Abstract][Full Text] [Related]
4. Obstetrical complications associated with abnormal maternal serum markers analytes.
Gagnon A; Wilson RD;
J Obstet Gynaecol Can; 2008 Oct; 30(10):918-932. PubMed ID: 19038077
[TBL] [Abstract][Full Text] [Related]
5. A risk prediction model for fetal hypospadias by testing maternal serum AFP and free beta-HCG.
Chen Y; Huang J; Mei J
Clin Biochem; 2019 Jul; 69():21-25. PubMed ID: 31152694
[TBL] [Abstract][Full Text] [Related]
6. [The value of maternal first and second trimester serum data of β-hCG, PAPP-A, AFP and uE3 in the prediction of preeclampsia].
Gu W; Lin J; Hou Y
Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):101-7. PubMed ID: 25877605
[TBL] [Abstract][Full Text] [Related]
7. Maternal serum second trimester AFP and hCG in pregnancies with placenta previa.
Heikkilä A; Heinonen S; Kirkinen P
Prenat Diagn; 2000 Feb; 20(2):100-2. PubMed ID: 10694682
[TBL] [Abstract][Full Text] [Related]
8. [Predictive value of abnormal second-trimester maternal serum triple screening markers for adverse pregnancy outcomes].
Hu Z; Liu X; Li L; Jia C; Li D; Liu R
Zhonghua Fu Chan Ke Za Zhi; 2014 Oct; 49(10):749-53. PubMed ID: 25537246
[TBL] [Abstract][Full Text] [Related]
9. Mid-trimester maternal serum AFP and hCG as markers of preterm and term adverse pregnancy outcomes.
Tancrède S; Bujold E; Giguère Y; Renald MH; Girouard J; Forest JC
J Obstet Gynaecol Can; 2015 Feb; 37(2):111-6. PubMed ID: 25767942
[TBL] [Abstract][Full Text] [Related]
10. Predictive Value of Second-Trimester Biomarkers and Maternal Features for Adverse Pregnancy Outcomes.
Yefet E; Kuzmin O; Schwartz N; Basson F; Nachum Z
Fetal Diagn Ther; 2017; 42(4):285-293. PubMed ID: 28395283
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for placenta accreta.
Hung TH; Shau WY; Hsieh CC; Chiu TH; Hsu JJ; Hsieh TT
Obstet Gynecol; 1999 Apr; 93(4):545-50. PubMed ID: 10214831
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of maternal alpha-fetoprotein variants in second-trimester biochemical screening for trisomy 21 and 18.
Chen Y; Chen Y; Ning W; Zhang W; Li L; Wang X; Yin Y; Zhang H
Sci Rep; 2022 Aug; 12(1):13605. PubMed ID: 35948592
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic significance of specific proteins of pregnancy in women with a uterine scar and placenta accreta.].
Borovkov VA; Igitova MB; Korenovskiy YV; Dudareva YA
Klin Lab Diagn; 2020; 65(6):353-357. PubMed ID: 32459893
[TBL] [Abstract][Full Text] [Related]
14. Elevated second-trimester maternal serum β-human chorionic gonadotropin and amniotic fluid alpha-fetoprotein as indicators of adverse obstetric outcomes in fetal Turner syndrome.
Alvarez-Nava F; Soto M; Lanes R; Pons H; Morales-Machin A; Bracho A
J Obstet Gynaecol Res; 2015 Dec; 41(12):1891-8. PubMed ID: 26369382
[TBL] [Abstract][Full Text] [Related]
15. Maternal serum markers, characteristics and morbidly adherent placenta in women with previa.
Lyell DJ; Faucett AM; Baer RJ; Blumenfeld YJ; Druzin ML; El-Sayed YY; Shaw GM; Currier RJ; Jelliffe-Pawlowski LL
J Perinatol; 2015 Aug; 35(8):570-4. PubMed ID: 25927270
[TBL] [Abstract][Full Text] [Related]
16. The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns.
Sayin NC; Canda MT; Ahmet N; Arda S; Süt N; Varol FG
Arch Gynecol Obstet; 2008 Jan; 277(1):47-53. PubMed ID: 17653738
[TBL] [Abstract][Full Text] [Related]
17. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome.
Spencer K; Crossley JA; Aitken DA; Nix AB; Dunstan FD; Williams K
Ann Clin Biochem; 2003 May; 40(Pt 3):219-31. PubMed ID: 12803832
[TBL] [Abstract][Full Text] [Related]
18. New cut-off values for screening of trisomy 21, 18 and open neural tube defects (ONTD) during the second trimester in pregnant women with advanced maternal age.
Chen Y; Wang X; Li L; Lu S; Zhang Z
BMC Pregnancy Childbirth; 2020 Dec; 20(1):776. PubMed ID: 33317474
[TBL] [Abstract][Full Text] [Related]
19. Identification of second trimester screen positive pregnancies at increased risk for congenital heart defects.
Jelliffe-Pawlowski LL; Walton-Haynes L; Currier RJ
Prenat Diagn; 2009 Jun; 29(6):570-7. PubMed ID: 19266536
[TBL] [Abstract][Full Text] [Related]
20. Prediction of preeclampsia or intrauterine growth restriction by second trimester serum screening and uterine Doppler velocimetry.
Audibert F; Benchimol Y; Benattar C; Champagne C; Frydman R
Fetal Diagn Ther; 2005; 20(1):48-53. PubMed ID: 15608460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
